Want to search for the relevant question and answer in your own language? Change the language in the dropdown menu above.
This guideline clarifies how users of NMP can ensure their compliance with the derived no-effect levels (DNELs) established in the restriction on 1-methyl-2-pyrrolidone (NMP) in entry 71 of Annex XVII to the REACH Regulation (EU) No 1907/2006. The guideline explains how to proceed when there are mandatory DNELs in addition to the occupational exposure limit values (OELs). It clarifies what the user needs to do to adequately control the risks. Several examples of good practice illustrate the type of equipment some companies have in place to control inhalation and dermal exposure in various tasks such as transfers, maintenance and sampling. In addition, examples of monitoring methods, including biological monitoring methods, are described. The document has been prepared in close cooperation with the industry stakeholders and endorsed by the Member States authorities.
In your language: